Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Visceral Leishmaniosis (VL) during the recruitment period that are EITHER treated for VL relapse and have a documented negative test of cure (TOC), OR are treated for primary VL and have a documented CD4 \<200 or WHO stage 4 disease during the recruitment period and have a documented negative TOC~* Patients treated for VL in the past with documented CD4 \<200 or WHO stage 4 disease during the recruitment period AND documented negative TOC after the latest VL treatment and currently asymptomatic OR currently negative diagnostic test (microscopy)~* Patients agreeing to start or continue antiretroviral treatment (first or second line)~* Patients willing to provide written informed consent~Exclusion Criteria:~* Patients with known hypersensitivity to pentamidine~* Patients with known renal failure~* Patients with diabetes mellitus (type I or II)~* Patients unlikely to attend follow-up visits/comply with study requirements~* Pregnant and lactating women~* Any other condition that could increase the risk of toxicity of pentamidine to such an extent outweighing the expected benefit (eg severe cardiac dysfunction).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentamidine Secondary Prophylaxis (PSP) (Type: EXPERIMENTAL): Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).